when will eli lilly release retatrutide stock jumps on Phase 3 weight loss results Retatrutide produces up to 30.3%

For standard review drugs like retatrutide, the PDUFA date is set 10 months after filing

Existing GLP1R agonists come with boxed warnings of thyroid cancer and pancreatitis, based mainly on rodent studies, where the effects of GLP1R agonism have noted species differences (For example, weight loss in rodents is mainly due to increased energy expenditure, whereas in humans it occurs via less food intake [54] )

The result is a decrease in ectopic fat storagea hallmark of insulin resistance and NAFLD

Retatrutide and liraglutide are two weight loss peptides that work by interacting with GLP-1 receptors in the brain, notably in areas crucial for appetite regulation, such as the hypothalamus [21]